-
Company Insights
Innovation and Patenting activity of CEL-SCI Corp Q4 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of CEL-SCI Corp Q4 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will be delivered...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Dapansutrile in Osteoarthritis Pain
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Dapansutrile in Osteoarthritis Pain report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Dapansutrile in Osteoarthritis Pain Drug Details: Dapansutrile (OLT-1177) is under development for...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Dapansutrile in Systolic Heart Failure
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Dapansutrile in Systolic Heart Failure report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Dapansutrile in Systolic Heart Failure Drug Details: Dapansutrile (OLT-1177) is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Abobotulinumtoxina in Migraine
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Abobotulinumtoxina in Migraine report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Abobotulinumtoxina in Migraine Drug Details: Abobotulinumtoxin A (Dysport, Botulinum Toxin Type A, Azzalure)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Ivonescimab in Non-Small Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Ivonescimab in Non-Small Cell Lung Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Ivonescimab in Non-Small Cell Lung Cancer Drug Details: Ivonescimab (AK-112)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – BGB-16673 in Chronic Lymphocytic Leukemia (CLL)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - BGB-16673 in Chronic Lymphocytic Leukemia (CLL) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. BGB-16673 in Chronic Lymphocytic Leukemia (CLL) Drug Details: BGB-16673 is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – BGB-16673 in Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - BGB-16673 in Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. BGB-16673 in Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma) Drug Details: BGB-16673 is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – JANX-008 in Non-Small Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - JANX-008 in Non-Small Cell Lung Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. JANX-008 in Non-Small Cell Lung Cancer Drug Details: JANX-008...
-
Product Insights
Pandemic Influenza – Drugs In Development, 2023
Global Markets Direct’s, ‘Pandemic Influenza - Drugs In Development, 2023’, provides an overview of the Pandemic Influenza pipeline landscape. The report provides comprehensive information on the therapeutics under development for Pandemic Influenza, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...